Drug Profile
Research programme: cell therapies - Juno Therapeutics/MSKCC/Eureka
Latest Information Update: 21 Jun 2022
Price :
$50
*
At a glance
- Originator Juno Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Multiple myeloma
Most Recent Events
- 21 Jun 2022 Early research is ongoing in the US (Eureka Therapeutics pipeline, June 2022)
- 28 Dec 2020 No recent reports of development identified for research development in Multiple-myeloma in USA (IV)
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation